Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $49.4 million.

  • 4D Molecular Therapeutics' Total Non-Current Liabilities rose 7.83% to $54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year increase of 7.83%. This contributed to the annual value of $49.4 million for FY2024, which is 55.77% up from last year.
  • As of FY2024, 4D Molecular Therapeutics' Total Non-Current Liabilities stood at $49.4 million, which was up 55.77% from $31.7 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Total Non-Current Liabilities peaked at $49.4 million during FY2024, and registered a low of $30.1 million during FY2020.
  • For the 3-year period, 4D Molecular Therapeutics' Total Non-Current Liabilities averaged around $37.1 million, with its median value being $31.7 million (2023).
  • Per our database at Business Quant, 4D Molecular Therapeutics' Total Non-Current Liabilities decreased by 11.32% in 2022 and then surged by 55.77% in 2024.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Total Non-Current Liabilities stood at $30.1 million in 2020, then grew by 13.54% to $34.2 million in 2021, then declined by 11.32% to $30.3 million in 2022, then climbed by 4.61% to $31.7 million in 2023, then spiked by 55.77% to $49.4 million in 2024.